癌症正在成为全球威胁,因为它的治疗面临许多挑战。因此,新发明优先考虑开发新的抗癌剂的要求。在这种情况下,激酶已被专门研究和开发为抗癌方案的有希望的新型药物靶标。吲哚衍生物已被发现是最有效的靶向多种激酶,比如PIM,CDK,TK,AKT,SRC,PI3K,PKD,GSK,等。,抑制癌细胞增殖。最近,一组研究人员提出了他们与该部分相关的研究成果,如张等人。通过在吲哚环的第4位取代描述了一些有效的PI3K抑制剂。Kassis等人。通过取代吲哚环的第2和第6位列举了几种有效的CDK5抑制剂。在本次审查中,我们主动总结了吲哚衍生物作为激酶抑制剂的结构-活性关系(SAR)研究,以开发潜在的抑制剂。
Cancer is becoming a global threat as its treatment accounts for many challenges. Hence, newer inventions prioritize the requirement of developing novel anticancer agents. In this context, kinases have been exclusively investigated and developed as a promising and novel class of drug targets for anticancer regimen. Indole derivatives have been found to be most effective for targeting multiple kinases, such as PIM, CDK, TK, AKT, SRC, PI3K, PKD, GSK, etc., to inhibit cell proliferation for cancer. Recently, a group of researchers have proposed their research outcomes related to this moiety, such as Zhang et al. described some potent PI3K inhibitors by substitution at the 4th position of the indole ring. Kassis et al. enumerated several potent CDK5 inhibitors by substituting the 2nd and 6th positions of the indole ring. In the present review, we have taken the initiative to summarize structure-activity relationship (SAR) studies of indole derivatives as kinase inhibitors for the development of potential inhibitors.